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Abstract Introduction: For dec-
ades, clinicians dealing with
immunocompromised and critically ill
patients have perceived a link
between Candida colonization and
subsequent infection. However, the
pathophysiological progression from
colonization to infection was clearly
established only through the formal
description of the colonization index
(CI) in critically ill patients. Unfortu-
nately, the literature reflects intense
confusion about the pathophysiology
of invasive candidiasis and specific
associated risk factors. Meth-
ods: We review the contribution of
the CI in the field of Candida infection
and its development in the 20 years
following its original description in
1994. The development of the CI
enabled an improved understanding of
the pathogenesis of invasive candidi-
asis and the use of targeted empirical
antifungal therapy in subgroups of
patients at increased risk for infection.
Results: The recognition of specific
characteristics among underlying
conditions, such as neutropenia, solid
organ transplantation, and surgical
and nonsurgical critical illness, has
enabled the description of distinct
epidemiological patterns in the
development of invasive candidiasis.
Conclusions: Despite its limited
bedside practicality and before con-
firmation of potentially more accurate
predictors, such as specific biomark-
ers, the CI remains an important way
to characterize the dynamics of colo-
nization, which increases early in
patients who develop invasive
candidiasis.
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Candida spp. colonization occurs in up to 80 % of critically
ill patients after 1 week in intensive care [1–3]. This very high
proportion contrasts strongly with the low rate of invasive
candidiasis in less than 10 % of them [4, 5]. Despite recent
advances in microbiological techniques, early diagnosis of
invasive candidiasis remains problematic and microbiologi-
cal documentation often occurs late in the course of infection
[6–8]. This explains its high crude and attributable mortality,
i.e., in the range reported for septic shock [9–11].
Early empirical treatment of severe candidiasis has
improved survival, but is responsible for the overuse of
antifungals [12–14]. This overuse not only contributes to
a huge financial burden, but has also promoted a shift to
Candida species with reduced susceptibility to antifungal
agents [15, 16]. Unfortunately, recent guidelines resulting
from expert consensus failed to provide high-level rec-
ommendations about empirical antifungal treatment or to
clarify the nature of such treatment strategies [8, 17, 18].
Despite limited levels of evidence, empirical treatment
currently relies on the positive predictive value of risk
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assessment strategies, such as the colonization index (CI),
Candida score, and predictive rules based on combina-
tions of risk factors [19–21].
Improved knowledge of the pathophysiological spec-
ificities of invasive candidiasis should promote better use
of clinical tools in the evaluation of patients who could
truly benefit from early antifungal therapy [22]. In con-
trast to most bacterial infections, invasive candidiasis is
characterized by a 7–10-day delay between exposure to
risk factors and infection development [23–25]. This time
window provides a unique opportunity for the imple-
mentation of a structured approach to the rigorous
selection of patients likely to benefit from early empirical
antifungal treatment [19, 26].
The CI is the most widely studied clinical tool for the
early risk assessment of invasive candidiasis among at-
risk patients. The primary objective of this review is to
highlight its role in this setting. The use of colonization
dynamics, as assessed by the CI, for the early detection of
patients likely to benefit from early antifungal treatment is
also explored in comparison with other tools currently
available in clinical practice. Finally, we also propose a
research agenda for the next decade.
Pathophysiology of invasive candidiasis
Nosocomial exogenous transmission of Candida has been
well described [27]. Of note, both endogenous and
exogenous colonization can co-exist in the clinical setting
[1]. However, carefully designed studies using genotyping
of Candida strains confirmed that endogenous coloniza-
tion is responsible for the large majority of severe
candidiasis [28, 29].
The epidemiology of invasive candidiasis has some
important differences in immunocompromised and criti-
cally ill patients (Fig. 1).
Neutropenic and bone marrow transplant recipients
Neutrophils are essential in the defense against invasive
candidiasis [30]. Their prolonged absence in neutropenic
patients or those with functional impairment after bone
marrow transplantation, combined with the selective
pressure of frequent and repetitive exposure to antibacte-
rial agents, plays a major role in the development of
invasive candidiasis in these patients. A high density of
Candida spp. on mucosal surfaces injured by chemother-
apy develops progressively and is responsible for fungal
translocation with a high risk of candidemia. The use of
systematic antifungal prophylaxis in the past three decades
explains the epidemiology of Candida infection, typi-
cally characterized by breakthrough invasive candidiasis
[31, 32]. Infection is almost always caused by a Candida
strain resistant to the antifungal agent used [15, 33].
Solid organ transplant recipients
Anti-rejection therapy increases the risk for Aspergillus
and other filamentous fungal infections in solid organ
transplant recipients, except among those receiving small
bowel and liver transplants, in whom additional specific
surgical factors further modify the epidemiology of dis-
ease [34, 35]. Prolonged and intense impairment of
cellular T cell-mediated immune response may contribute
to the high proportion of cutaneous and mucosal candi-
diasis [36]. This factor has justified the use of systematic
antifungal prophylaxis in these patients in whom, as
among neutropenic patients and bone marrow transplant
recipients, breakthrough Candida spp. infection develops
with strains resistant to the agent used [18].
Nonsurgical critically ill patients
In nonsurgical critically ill patients, the continuous and
prolonged support of failing organs and the selective
pressure of broad-spectrum antibiotics constitute key risk
factors for invasive candidiasis. Support of organ failure
requires the use of numerous devices, such as intravas-
cular catheters, endotracheal tubes, naso- and oro-gastric
tubes, and Foley catheters, which are frequently colonized
by Candida spp. as a result of the high affinity of their
biofilm [1]. These specificities may explain progressive
colonization in a high proportion of patients after pro-
longed stay in the intensive care unit (ICU) [6, 37, 38].
They may also explain a higher proportion of catheter-
related infections in the absence of severe immune
impairment [39]. In this context, the role of exposure to
steroids largely used to improve the speed of recovery
from circulatory failure remains to be determined.
Limited data are available on the usefulness of pro-
phylaxis and recent guidelines did not include
recommendation for antifungal prophylaxis in nonsurgi-
cal critically ill patients [17, 18, 40].
Critically ill patients recovering from abdominal
surgery
Additional factors should be considered in patients after
abdominal surgery [41]. Any perforation or opening of the
digestive tract results in contamination of the peritoneum
by bowel flora. In most cases, surgical cleaning of the
abdominal cavity, eventually combined with antibiotics, is
sufficient to allow full recovery [42]. Except for patients
presenting with nosocomial peritonitis and some of those
presenting with septic shock and multiple organ failure,
the identification of Candida spp. has no clinical signifi-
cance under these conditions [22]. Recurrent peritonitis
following anastomotic leakage or persistent inflammation
may be required for the progression of Candida spp.
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Fig. 1 Pathophysiology of invasive candidiasis in different patient populations. Detailed mechanisms are summarized in the
corresponding sections of the text
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colonization to invasive candidiasis [43]. However, the
development of invasive candidiasis requires concomitant
exposure to additional factors, such as an increasing
amount of Candida spp. in a non-functioning bowel,
prolonged antibiotic treatment, and/or requirement for
organ support. In contrast to nonsurgical patients, these
particularities explain why a high proportion of invasive
candidiasis cases do not manifest with candidemia and
develop only late in the course of the disease [44].
Non-candidemic invasive candidiasis includes intra-
abdominal abscess and peritonitis defined by one of the
following culture results from specimens obtained at sur-
gery: (1) monomicrobial growth of Candida spp.; (2) any
amount of Candida spp. growth within a mixed-flora
abscess; or (3) moderate or heavy growth of Candida spp. in
mixed-flora peritonitis treated with appropriate antibacte-
rial therapy according to susceptibility testing [43–46].
Two small prospective studies, including one placebo-
controlled, suggested that antifungal prophylaxis in
patients presenting with anastomotic leakage after
abdominal surgery may prevent the development of
invasive candidiasis [18, 45, 46].
In patients with severe acute necrotizing pancreatitis,
invasive candidiasis develops with similar pathophysio-
logical characteristics. Progressive colonization of the
bowel within the first 2 weeks of the disease results in
translocation into necrotic tissues, and fungal infections
have been documented in up to 10 % of patients not
exposed to antibiotics.
Critically ill patients with Candida isolated
from the respiratory tract
Candida spp. colonization of the airway is frequently
reported in mechanically ventilated critically ill patients,
and its clinical significance is difficult to evaluate. Can-
dida has a low affinity for alveolar pneumocytes and
histologically documented pneumonia has been rarely
reported. Hematogenous dissemination in the context of
candidemia [1] may be responsible for multiple pulmon-
ary abscesses and should be viewed as a distinct entity.
Hence the existence of true candidal pneumonia is
doubtful and recovery of Candida spp. from the respira-
tory tract should generally be considered as colonization
and does not justify antifungal therapy [17–19].
Candida colonization
The distinction between patients with Candida spp. col-
onization who did not require treatment and those likely
to develop invasive infection was identified as a difficult
clinical challenge in the field of infectious diseases more
than 40 years ago [47]. After the description in the early
1970s of Candida infection in surgical patients, mani-
festing as ‘‘disseminated candidiasis’’ and characterized
by persistent fungemia and multiple disseminated mic-
roabscesses on autopsy, several authors reported that it
might be preceded by fungal colonization. Klein and
Watanakunakorn [48] reported the presence of visceral
microabscesses in up to 30 % of patients with Candida
spp. colonization and recommended treatment of all such
patients with critical illness or persistent candidemia.
Solomkin et al. confirmed this concept in a detailed
review of 63 surgical patients with postoperative candi-
demia. Among 51 patients who developed candidemia as a
late complication of intra-abdominal infection, adequate
antifungal treatment ([3 mg/kg amphotericin B) resulted
in survival of 10/15 patients compared with 6/36 untreated
patients. Autopsies revealed visceral Candida spp. mic-
roabscesses in 7/20 patients [42, 49]. Moreover, a digestive
fungal source was identified in nearly all patients, and
candidemia was considered to originate from intestinal
Candida spp. growth in the presence of mucosal loss.
Calandra et al. provided further evidence of the clinical
significance of Candida colonization of the peritoneum in
surgical patients [39]. In a series of 49 patients with
spontaneous perforation (n = 28) or surgical opening of
the digestive tract (n = 21), 19 (39 %) patients developed
invasive candidiasis, including 7 cases of intra-abdominal
abscesses and 12 cases of peritonitis [43]. Invasive can-
didiasis developed significantly more frequently in patients
who had undergone surgery for acute pancreatitis than in
those with gastrointestinal perforations (90 vs. 32 %,
p = 0.005) or other disorders, such as diseases of the bil-
iary tract or colon (90 vs. 17 %, p = 0.003). Invasive
candidiasis was associated significantly with an initially
high or increasing amount of Candida spp., as assessed by
semiquantitative cultures. Compared with uninfected
patients, Candida spp. showed light, moderate, and heavy
growth from the first positive specimen in 26 (87 %) vs. 9
(47 %), 4 (13 %) vs. 6 (32 %), and 0 vs. 4 (21 %) infected
patients, respectively (p = 0.005). Moreover, the amount
of Candida spp. cultured from subsequent specimens
increased in 15 (79 %) infected patients and only 2 (7 %)
uninfected patients (p \ 0.001) [39].
Candida colonization index: the missing link
In the early 1990s, the origin of Candida spp. infection
was highly debated [50]. Whether the infection was
exogenous or endogenous in origin, and whether patients
could become colonized with strains from the surrounding
environment or with their ‘‘own’’ strains of Candida spp.
was uncertain. We tested the hypothesis that yeast colo-
nization would precede infection in critically ill patients
[23]. We determined the genotypic characteristics of 322
Candida spp. collected prospectively from 29 critically ill
1432
patients who developed significant colonization under
routine culture surveillance two to three times weekly
over a 6-month period. These patients belonged to a
cohort of 650 surgical ICU patients. Significant coloni-
zation was defined as the presence of Candida spp. in
three or more samples taken from one or more sites on at
least two consecutive screening days. Candida spp.
strains isolated from an individual patient had an identical
genetic pattern, even when isolated from different body
sites, and this pattern remained the same over a prolonged
period of up to 140 days. No horizontal transmission
could be demonstrated during the study period. Invasive
candidiasis, including 8 cases of candidemia, occurred in
11/29 (38 %) patients. All patients who developed
infection had previous colonization by strains with iden-
tical genetic patterns. Our intensive surveillance failed to
document cross-transmission of Candida spp. between
colonized and non-colonized patients.
Colonization index
The development of the CI has been viewed as a major
conceptual advance in the characterization of supporting
the progression from colonization to infection in surgical
patients.
The Candida CI is defined as the ratio of the number of
distinct non-blood body sites colonized by Candida spp. to
the total number of body sites cultured [24]. With the
exception of blood cultures, samples collected from body
sites other than those routinely screened are also considered
in the CI (Table 1). Only strains of Candida spp. with the
same genetic identity are considered in calculating the CI.
All 29 included patients were heavily colonized with
Candida spp., but with no significant difference in the
reason for ICU admission and comorbidities between
infected and uninfected patients. The Acute Physiology
and Chronic Health Evaluation II (APACHE II) score and
duration of antibiotic exposure before colonization were
higher among the 11 patients who ultimately developed
invasive candidiasis. In these patients, colonization pre-
ceded infection by an average of 25 days (range 6–70).
The 18 patients who did not develop infection were col-
onized for a mean of 29 days (range 5–140). A total of
153 [5.3 ± 1 (range 3–8) per patient] distinct body sites
were tested, and this number did not differ significantly
between the two groups of patients.
The CI was calculated daily, and the highest values
obtained before invasive candidiasis development were
compared with those recorded for patients who did not
develop candidiasis. The average CI differed significantly
between colonized and infected patients (0.47 vs. 0.70,
p \ 0.01). All patients who ultimately developed infec-
tion reached the threshold value of 0.5 before infection
(Fig. 2). Importantly, infected patients reached the
threshold CI value an average of 6 days (range 2–21)
Table 1 Description of the colonization index
Index Definition Formula
Colonization index (CI) Ratio of the number of distinct non-blood body sites
colonized by Candida spp. to the total number of
body sites cultured. With the exception of blood
cultures, samples collected from body sites other
than those routinely screened are also considered.
Only strains of Candida spp. with identical
electrophoretic karyotypes are considered when
calculating the CI
CI¼ Number of sites colonized
Number of sites cultured
Corrected colonization
index (CCI)
Product of the CI and the ratio of the number of
distinct body sites showing heavy growth (???
from semi-quantitative culture or B105 in urine or
gastric juice) to the total number of body sites with
Candida spp. heavy growth
CCI ¼ Number of sites colonized
Number of sites cultured
 Number of sites with heavy growth
Total positive sites
Use of the CIa In patients perceived to be at risk of developing an
invasive candidiasis: twice weekly surveillance
culture of the following sitesb:
- Oropharynx swab or tracheal secretions
- Gastric fluid
- Perinea swab or stool sample
- Urine sample
- Surgical wound swab or drained abdominal fluids
- Catheter insertion sites
a Identification of Candida species at the genetic level has only
been performed in the original study. However, different species of
Candida may contribute to the burden of fungi which will eventually
result in symptomatic infection. Accordingly, we suggest to con-
sider all species of Candida identified for the calculation of the CI
b Except for specific invasive candidiasis discussed in the section
on pathophysiology of non-candidemic invasive candidiasis, Can-
dida spp. isolated from these sites should be considered as
colonization
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before candidiasis. All but one patient reached this
threshold at least 3 days before the time of infection. The
sensitivity, specificity, and positive and negative predic-
tive values of the CI were determined to be 100, 69, 66,
and 100 %, respectively.
Corrected colonization index
In a post hoc analysis, we developed the corrected colo-
nization index (CCI) by taking into account the amount of
Candida spp. recovered by semiquantitative cultures [24].
The CCI is the product of the CI and the ratio of the
number of distinct body sites showing heavy growth
(??? or at most 105 in urine or gastric juice) to the total
of distinct body sites with Candida spp. growth (Table 1).
The mean CCI differed significantly between colo-
nized (0.16) and infected (0.56) patients (p \ 0.01). CCIs
were less than 0.35 in all colonized patients and at least
0.4 in all infected patients (p B 0.001). The sensitivity,
specificity, and positive and negative predictive values
were all 100 %. In a multiple logistic regression analysis,
only the APACHE II score [odds ratio (OR), 1.03; 95 %
confidence interval, 1.01–1.05 per point; p = 0.007] and
CCI (OR, 4.01; 95 % confidence interval, 2.16–7.45;
p \ 0.001) independently predicted the development of
invasive candidiasis.
Overview of the usefulness of the colonization index
Since the publication of the paper describing the CI in
1994 in Annals of Surgery, many centers have used the CI
or a methodology derived from its original description to
assess the dynamics of Candida colonization in different
subgroups of critically ill patients at risk of invasive
candidiasis. Unfortunately, these data have not been val-
idated in large multicenter trials.
Several studies have indirectly suggested the validity
and potential usefulness of the CI, but almost exclusively
in surgical patients (Table 2). This index has been used to
characterize colonization dynamics [37, 38, 51–55],
assess the significance of candiduria in critically ill
patients [38, 56–59], and evaluate the impact of anti-
fungal prophylaxis in subgroups of patients at risk of
candidiasis [40, 46, 60–63]. At least four studies have
reported the use of the CI to guide empirical antifungal
treatment. Although major methodological flaws may
preclude the validation of their findings, this application
reduced the incidence of ICU-acquired invasive candidi-
asis in all four studies (Table 3) [57, 64–66].
Dubau et al. [57] prospectively monitored CIs weekly
in 89/669 consecutive patients staying in the ICU for
more than 7 days after digestive surgery who had pro-
tein C levels greater than 100 mg/l or received antibiotic
treatment for more than 7 days. All patients developing
a CI above 0.5 were empirically treated with antifungals
until it decreased below 0.5. The proportion of patients
with CIs greater than 0.5 increased from 6 to 25, 40, 55,
and 59 % after 1, 2, 3, 4, and more than 4 weeks,
respectively. Only one of the 35 patients with CIs
greater than 0.5 who were empirically treated with
antifungal medications developed candidiasis; the degree
of colonization decreased rapidly in the other 34
patients.
In a before/after trial, Piarroux et al. [64] prospectively
used weekly CIs and CCIs to assess the intensity of
Candida spp. colonization in 478 surgical patients staying
in the ICU. Patients with CCIs greater than 0.4 received
empirical antifungal treatment. Compared with an his-
torical cohort of 455 control subjects, the incidence of
invasive candidiasis was lower among these patients (7.0
vs. 3.8 %; p = 0.03). Moreover, this strategy completely
prevented the development of ICU-acquired invasive
candidiasis. The proportions of patients treated empiri-
cally were 87 % of those with CCIs greater than 0.4
(some of them died before the CCI could be calculated),
18 % of those with CCIs less than 0.4 and CIs greater
than 0.5, and 2 % of those with CCIs less than 0.4. A total
of 25 % of patients received empirical antifungal treat-
ment. The authors estimated that 160 complete
mycological screenings and 10 preemptive antifungal
treatments were needed to prevent one proven ICU-
acquired invasive candidiasis. Despite the absence of
randomization, this study is the most valuable ever per-
formed using the CI to guide empirical antifungal
treatment. However, the intense laboratory work required
to perform CI in all ICU patients and the high proportion







Fig. 2 Colonization index. This index is defined as the ratio of the
number of distinct non-blood body sites with Candida spp.
colonization to the total number of distinct body sites tested. It
was recorded for each patient from the first day of colonization
until discharge from the intensive care unit (uninfected patients) or
severe candidiasis development (infected patients). Black circles
represent patients who developed severe candidiasis, white circles
represent patients who remained colonized. Reproduced with









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































currently used widely among non-immunocompromised
critically ill patients.
In a prospective study of 37 critically ill patients, Eren
et al. [65] found a correlation between the CI and the
presence of C. albicans antibodies. Among 26 patients
with C. albicans colonization, immunoglobulin M (IgM)
and IgG were found in 5/7 (71 %) patients with CIs
greater than 0.5, compared with only 3/12 (25 %) patients
with CIs less than 0.5 in whom serum could be tested
(total, n = 19) and 0/7 non-colonized patients in whom
serum could be tested (total, n = 11) [65]. The authors
stated, ‘‘in the follow-up of the patients, no candidemia
developed and this was thought to be due to the pre-
ventive measures which were taken especially in ICU
patients with CI [ 0.5,’’ suggesting that empirical anti-
fungal treatment was given to patients with CIs greater
than 0.5.
Comparison of the colonization index with other
predictive tools
The accuracy of the CI has been compared with that of
other surrogate markers of invasive candidiasis, such as
the Candida score, predictive rules, and, more recently,
beta-glucan (Table 4) [44, 67–72]. In a prospective study
of 89 high-risk surgical ICU patients (61 recurrent gas-
trointestinal tract perforation; 25 severe acute
pancreatitis) in whom 29 developed a non-candidemic
invasive candidiasis, Tissot el al. showed that two con-
secutive beta-glucan serum levels above 80 pg/ml
predicted early the development of infection with a sen-
sitivity, specificity, positive predictive value, and a
negative predictive value of 65, 78, 68 and 77 %,
respectively [44]. Similarly, a previous study by Posteraro
et al. [70] in a cohort of medical and surgical critically ill
patients staying more than 5 days and developing a severe
sepsis, in whom beta-glucan was higher than 80 pg/ml,
showed a sensitivity, specificity, positive predictive value,
and a negative predictive value of 93, 94, 72, and 99 %,
respectively for the early detection of invasive candidiasis
(16 episodes, including 13 candidemia). Overall, the
accuracy of CI is lower than other methods for the early
detection of patients at higher risk of infection. Never-
theless, the usefulness of beta-glucan to guide empirical
antifungal treatment remains to be determined.
Three industry-sponsored studies failed to demonstrate
the clinical usefulness of predictive rules combining var-
ious risk factors. A predictive rule was used in a
multicenter, randomized, double-blind, placebo-con-
trolled trial comparing caspofungin vs. placebo as
antifungal prophylaxis or preemptive treatment in 222
critically ill patients [73]. The rule combined ICU stay for
at least 3 days, mechanical ventilation, exposure to
antibiotics, the presence of a central line, together with at
least one additional risk factor among the following: par-
enteral nutrition, dialysis, surgery, pancreatitis, systemic
steroids, or other immune suppressive agents. The inci-
dence of invasive candidiasis was 16.7 % (14/84) vs.
9.8 % (10/102) in patients receiving placebo and caspo-
fungin, respectively (p = 0.14). When baseline infections
were included, it was 30.4 % (31/102) and 18.8 % (22/
117), for patients receiving preemptive placebo and ca-
spofungin, respectively (p = 0.04). Safety, length of ICU
stay, antifungal use, and mortality did not differ. The
authors concluded that caspofungin prophylaxis was safe
with a non-significant trend to reduce invasive candidiasis,
and that the preemptive therapy approach deserves further
study. Two recent and currently unpublished studies
attempt to use clinical predictive rules to guide empirical
antifungal treatment. The first, entitled ‘‘Pilot Feasibility
Study With Patients Who at High Risk For Developing
Invasive Candidiasis in a Critical Care Setting (MK-0991-
067 AM1’’ (ClinicalTrials.gov identifier: NCT01045798)
and conducted by the Mycoses Study Group, was termi-
nated because of a low recruitment rate after the inclusion
of only 15 patients and generation of uninterpretable data.
Preliminary results of the second study, entitled ‘‘A Study
to Evaluate Pre-emptive Treatment for Invasive Candidi-
asis in High Risk Surgical Subjects (INTENSE)’’
(ClinicalTrials.gov identifier: NCT01122368), showed a
high proportion of invasive candidiasis at study entry;
independent experts considered, however, that the major-
ity of salvage antifungal treatments were unjustified.
Globally, the proportion of invasive candidiasis develop-
ing in the group receiving preemptive antifungal treatment
was not different from that of the group receiving placebo,
but the number of patients excluded from the analysis
resulted in an underpowered analysis.
These outcomes illustrate a well-known paradigm of
accuracy. The use of the most sensitive test potentially
increases the number of patients who are uselessly treated
empirically. In contrast, the use of the most specific test
potentially increases the number of patients who do not
receive empirical antifungal treatment and in whom late
treatment could be associated with a worse outcome.
An ongoing prospective multicenter, double blind,
randomized-controlled French trial (EMPIRICUS) is
currently recruiting critically ill patients at risk of inva-
sive candidiasis. Patients mechanically ventilated for
more than 4 days with sepsis of unknown origin and with
at least one extra-digestive fungal colonization site and
multiple organ failure are eligible for randomization to
receive empirical micafungin or a placebo. This study
includes prospective determination of the CI among its
secondary endpoints and may help to develop guidelines
for treating non-immunocompromised patients with fun-









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The CI and other predictive tools (the Candida score
and predictive rules) have been specifically developed by
using their positive predictive value for the early identi-
fication of high-risk patients who will develop invasive
candidiasis. Nevertheless, it is relevant to note that the
negative predictive values of the CI and all other surro-
gate markers of invasive candidiasis are much higher than
their positive predictive values [21]. Among them, only
the negative predictive value of the Candida score has
been validated in a multicenter prospective clinical trial
[75].
Advantages and pitfalls of the use of colonization
index
To summarize the data reviewed on the use of the CI, its
main advantages are that it has been successfully used to
characterize colonization dynamics, assess the signifi-
cance of candiduria, and to evaluate the impact of
antifungal prophylaxis. A low CI has a high negative
predictive value for the further development of invasive
candidiasis. Among the pitfalls, it should be emphasized
that it is work-intensive with a limited bedside practica-
bility, that only limited data are available for nonsurgical
patients, and its cost-effectiveness and usefulness for the
management of critically ill patients remain to be proven
in large prospective clinical trials.
Further perspectives
These observations may pave the way for a new paradigm
in the research agenda of the early diagnosis of invasive
candidiasis and take advantage of the disease patho-
physiology characterized by a 7–10-day delay between
exposure to risk factors and infection. We propose a
stepwise approach to optimize the accuracy of the CI and
other clinical tools (Fig. 3).
Provided that preliminary results can be confirmed in
larger cohorts of patients [76], preliminary stratification
according to specific genetic polymorphisms could be
used as a preliminary step to increase the accuracy of
subsequent steps. The second step is to take advantage of
the high negative predictive values of the CI, Candida
score, and/or predictive rules. This strategy will reduce
the currently large proportion of useless antifungal treat-
ments, frequently started for nonobjective emotional
reasons. The enhanced intrinsic risk of invasive candidi-
asis in patients with increased risk identified after this
second step may further improve the accuracy of bio-
markers, such as mannan/anti-mannan antibodies and/or
b-glucan, applied in the third step. This approach should



































































































































































































































































































































































































































































































































































































































































































































































































































































benefit from early antifungal treatment and reduce
unnecessary overexposure to antifungal agents in patients
with a documented limited risk of infection.
Moreover, the high negative predictive value of the
predictive tools (CI, Candida score, and predictive rules)
for the further development of an invasive candidiasis
may allow one to stop empirical antifungal treatment
possibly prescribed before evaluating the patient accord-
ing to the proposed stepwise approach.
Conclusion
The development of the CI has enabled better appreciation
of the dynamics of Candida colonization in patients at
high risk of invasive candidiasis. It can still be used, as it is
in many institutions, for the early detection of patients at
high risk of invasive candidiasis and to guide empirical
antifungal treatment. Continued development and execu-
tion of clinical trials in this difficult field are important.
Until further progress can be achieved with new clinical
studies of specific biomarkers involving larger patient
cohorts, 20 years after its description, the CI remains one
of the best methods of characterizing the dynamics of
Candida colonization and identifying patients at very low
or increasing risk of invasive candidiasis.
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Fig. 3 Proposed study designs to select high-risk patients who
would truly benefit from early empirical antifungal treatment. First,
patients should be stratified according to pathophysiological
characteristics specific to invasive candidiasis (i.e., immunocom-
promised individuals, after digestive surgery, other critically ill
patients). The three-step approach: In a first optional step, increased
intrinsic risk of invasive candidiasis is identified by specific genetic
polymorphisms related to innate immunity. In the second step,
patients at low objective risk of invasive candidiasis are ruled out
by using the high negative predictive values of current risk-
assessment strategies (CI, Candida score, peritonitis score, predic-
tive rule). In the third step, empirical antifungal treatment is started
early in high-risk patients identified by increased biomarkers
values, such as beta-glucan performed only in patients retained by
who met criteria outlined in previous steps. A simplified approach
restricted to steps two and three may be also of potential interest
1445
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